Do you want to read an article? Please log in or register.
Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients
Lung, Respiratory and Thoracic Cancer
Related content
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts
★ 1
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Lung Cancer.
Früh M, Panje CM, Reck M, Blackhall F, Califano R, Cappuzzo F, Besse B, Novello S, Garrido P, Felip E, O'Brien M, Paz Ares L, de Marinis F, Westeel V, De Ruysscher D, Putora PM
doi: 10.1016/j.lungcan.2020.03.024.
Lung Cancer
Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.
1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
★ 3
Recommended by
Alexander Meisel, Faculty Member
Lung Cancer.
Subbiah V, Paz-Ares L, Besse B, Moreno V, Peters S, Sala MA, López-Vilariño JA, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Zaman K, López R, Ponce S, Boni V, Arrondeau J, Delord JP, Martínez M, Wannesson L, Antón A, Valdivia J, Awada A, Kristeleit R, Olmedo ME, Rubio MJ, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D' Arcangelo M, Santoro A, Villalobos VM, Sands J, Trigo J
doi: 10.1016/j.lungcan.2020.10.003.Visit the original publication at ncbi.nlm.nih.gov
Lung, Respiratory and Thoracic Cancer
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations
Drugs.
Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Chawla A, Rosell R, Corral J, Migliorino MR, Pluzanski A, Noonan K, Tang Y, Pastel M, Wilner KD, Wu YL
doi: 10.1007/s40265-020-01441-6.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status
★ 1
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
doi: 10.1016/j.ejca.2020.02.023.
Lung, Respiratory and Thoracic Cancer
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
Lancet Oncol.
Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV
doi: 10.1016/
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy
★ 1
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Lung Cancer.
Reck M, Syrigos K, Miliauskas S, Zöchbauer-Müller S, Fischer JR, Buchner H, Kitzing T, Kaiser R, Radonjic D, Kerr K
doi: 10.1016/j.lungcan.2020.08.004.
Lung, Respiratory and Thoracic Cancer
Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer
JAMA Oncol.
Kichenadasse G, Miners JO, Mangoni AA, Rowland A, Hopkins AM, Sorich MJ
doi: 10.1001/jamaoncol.2019.5241.
Lung, Respiratory and Thoracic Cancer
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials
J Clin Oncol.
Gridelli C, Morabito A, Cavanna L, Luciani A, Maione P, Bonanno L, Filipazzi V, Leo S, Cinieri S, Ciardiello F, Burgio MA, Bilancia D, Cortinovis D, Rosetti F, Bianco R, Gebbia V, Artioli F, Bordonaro R, Fregoni V, Mencoboni M, Nelli F, Riccardi F, di Isernia G, Costanzo R, Rocco G, Daniele G, Signoriello S, Piccirillo MC, Gallo C, Perrone F
doi: 10.1200/JCO.2017.76.8390.